Identification of Conjugation Sites in an Antibody Drug Conjugate

Significance of the topic

Antibody drug conjugates represent a fast growing class of targeted biotherapeutics. By linking a potent cytotoxic payload to a monoclonal antibody, ADCs deliver drugs specifically to diseased cells while reducing systemic toxicity. Precise identification of drug conjugation sites is critical for ensuring batch consistency, therapeutic efficacy, and safety.

Objectives and study overview

This study demonstrates a comprehensive workflow for mapping lysine conjugation sites in ado trastuzumab emtansine (T DM1). The goal is to confidently identify site specific attachments and evaluate method reproducibility and mass accuracy.

Methodology and sample preparation

Sample preparation and peptide mapping were automated using the AssayMAP Bravo platform. ADCs were denatured in urea and Tris buffer, reduced with DTT, alkylated with iodoacetamide, and digested with trypsin. The digest was quenched with trifluoroacetic acid and analyzed by LC Q TOF.

Used instrumentation

• Agilent AssayMAP Bravo protein sample prep platform
• Agilent 1290 Infinity II bio LC system with peptide mapping column
• Agilent 6545XT AdvanceBio LC Q TOF system
• Agilent MassHunter BioConfirm software 12.1

Results and discussion

The workflow achieved 94 percent sequence coverage and identified 26 MCC DM1 conjugation sites across light and heavy chains. Mass accuracy for drug conjugated peptides was within 3 ppm. UV and extracted ion chromatograms confirmed the retention and fragmentation patterns of modified peptides. High reproducibility was demonstrated by retention time RSDs below 0.3 percent and signal intensity RSDs around 5 percent.

Benefits and practical applications

• Enables detailed mapping of heterogeneous lysine conjugation profiles
• Supports quality control and batch comparability in ADC development
• Facilitates structure activity relationship studies and linker optimization

Future trends and applications

Advances may include integration of high throughput automation, machine learning driven data analysis for faster site assignment, and application to novel linker chemistries. Emerging high resolution MS platforms could further enhance sensitivity and accuracy.

Conclusion

The Agilent peptide mapping workflow combining AssayMAP Bravo automation, 1290 Infinity II LC, and 6545XT LC Q TOF provides a robust, accurate, and reproducible approach for identifying ADC conjugation sites. This platform supports comprehensive characterization essential for ADC development.

References

• Wu G H Gao Y B Liu D T Tan X D Hu L D Qiu Z D Liu J Y He H D Liu Y J Study on the Heterogeneity of T DM1 and the Analysis of the Unconjugated Linker Structure under a Stable Conjugation Process ACS Omega 2019 4 8834 8845
• Lewis Phillips G D Li G Dugger D L Crocker L M Parsons K L Mai E Blattler W A Lambert J M Chari R V J Lutz R J Targeting HER2 Positive Breast Cancer with Trastuzumab DM1 an Antibody Cytotoxic Drug Conjugate Cancer Res 2008 68 9280 9290